Immatics US is the lead sponsor of 4 current clinical trials in our USA, UK and EU (CTIS) registers. 3 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are IMA203, Nivolumab and Albumin-Bound Paclitaxel. The most-studied condition is Melanoma, Cutaneous Malignant.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126 · ClinicalTrials.gov ↗ · Melanoma, Cutaneous Malignant
|
Phase 3 | Recruiting | 2025-01 | UK, USA |
|
ACTengine® IMA203 Combined With mRNA-4203
NCT06946225 · ClinicalTrials.gov ↗ · Cutaneous Melanoma, Synovial Sarcoma
Drug: IMA203 |
Phase 1 | Recruiting | 2025-07 | USA |
|
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT03686124 · ClinicalTrials.gov ↗ · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
Drug: Nivolumab |
Phase 1/2 | Recruiting | 2019-05 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Immatics US as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors
2026-525827-25-00 · Neoplasms
Drug: IMA203 |
Phase 1 | Authorised | Germany |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 3 |
| Clinical trials in UK | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers.
Immatics US is the lead sponsor of 3 current trials on ClinicalTrials.gov in our USA and UK registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 11 drugs and biologicals as interventions. The most frequent are IMA203 (3), Nivolumab (2), Albumin-Bound Paclitaxel (1), Carboplatin (1) and Dacarbazine (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.